Esperion Therapeutics Sues Aurobindo Pharma in Patent Dispute

Esperion Therapeutics sued Aurobindo Pharma and related defendants in a patent dispute over bempedoic acid, the active ingredient in Esperion's cholesterol drug Nexletol. The case is docketed as 24-cv-06348. Filing details and the assigned judge are not yet confirmed in the public record.

The case was recently reassigned by court order on April 20, 2026. Reassignments at this stage typically signal an administrative transfer between judges or a consolidation with related litigation — not a ruling on the merits. The reason for the reassignment has not been stated on the docket.

Patent cases in the pharmaceutical space often follow a predictable track: the branded manufacturer sues after a generic company files an Abbreviated New Drug Application (ANDA) with the FDA, triggering a 30-month stay on generic approval. Whether that procedural posture applies here has not been confirmed from the current docket record.

The substantive fight, when it comes, will center on whether Aurobindo's generic version of bempedoic acid infringes Esperion's patents and whether those patents are valid. Esperion has faced prior patent challenges to Nexletol, so this litigation fits a pattern the company has handled before.